SonoVue

Phase 3Small molecule

BBracco Diagnostics, Inc

SonoVue is one of 122 small molecule programs targeting Portal Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal HypertensionActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Prostate CancerActive, not recruiting

UltrasoundRecruiting

Pilot StudyCompleted

Portal HypertensionPreclinical

Active, not recruiting

Pancreatic AdenocarcinomaPreclinical

Active, not recruiting

Prostate CancerPreclinical

Active, not recruiting

UltrasoundPhase 3

Recruiting

Pilot StudyPreclinical

Completed

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

12 2

Talzenna

Pfizer

Phase 3

9 3

Rubraca

Bristol-Myers Squibb

Phase 3

9 4

Leuprorelin

Takeda

Phase 3

9 5

Antibiotic

Pfizer

Phase 3

1 6

SonoVue

BBracco Diagnostics, Inc

Phase 3

2 7

Aglatimagene Besadenovec

CCandel Therapeutics, Inc.

Phase 3

2 8

AAA817

Novartis

Phase 3

1 9

INR101

YYunhe Pharmaceutical (Tianjin) Co., Ltd

Phase 3

3 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Intravenous

NCT07113808

Q4 2026

N/ANot yet recruiting

Portal Hypertension

NCT07365709

Q2 2029

Phase 3Recruiting

Ultrasound

NCT06497959

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Multiparametric Ultrasound Imaging in Prostate Cancer

Unknown status·—·N/A·NCT03101176·200 enrolled

Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer

Terminated·—·N/A·NCT01481441·208 enrolled

Ultrasound2 trials

Study of Placental Vascularization Using Contrast Ultrasound

Recruiting·—·Phase 3·NCT06497959·30 enrolled

SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization

Completed·BBracco Diagnostics, Inc·Phase 3·NCT00829413·353 enrolled

Colorectal Cancer1 trial

Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer

Completed·SSt. Olavs Hospital·Phase 1/2·NCT03477019·17 enrolled

Stroke1 trial

Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)

Terminated·UUmeå University·Phase 3·NCT03290053·1 enrolled

Breast Cancer1 trial

KVUS at Neoadjuvant CTx of Breast Cancer

Unknown status·RRWTH Aachen University·Phase 3·NCT03385200·60 enrolled

7 more indications

Efficacy and Safety1 trial

An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging

Completed·GGE Healthcare·Phase 3·NCT03335566·424 enrolled

Portal Hypertension1 trial

Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension

Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07365709·107 enrolled

Pancreatic Adenocarcinoma1 trial

Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma

Completed·SSociété Française d'Endoscopie Digestive·N/A·NCT01765036·100 enrolled

Echocardiography1 trial

Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)

Withdrawn·UUniversity Hospital, Basel, Switzerland·Phase 1/2·NCT00286559

Pilot Study1 trial

A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions

Completed·UUniversity Hospital, Tours·N/A·NCT00243698·59 enrolled

Hemodynamic1 trial

Safety of SonoVue on Pulmonary Hemodynamics

Completed·BBracco Diagnostics, Inc·Phase 2·NCT01306292·36 enrolled

Intravenous1 trial

Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine··NCT07113808·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for SonoVue. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SonoVue compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SonoVue. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBracco Diagnostics, Inc

SonoVue

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2029

Trials by Indication[1]

Prostate Cancer2 trials

Ultrasound2 trials

Colorectal Cancer1 trial

Stroke1 trial

Breast Cancer1 trial

Efficacy and Safety1 trial

Portal Hypertension1 trial

Pancreatic Adenocarcinoma1 trial

Echocardiography1 trial

Pilot Study1 trial

Hemodynamic1 trial

Intravenous1 trial

References

Drug Info

Quick Facts

Related News